Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: Opinions of three experts – III

Hellenic Journal of Cardiology

Volumn 56, Issue 1, 2015, Pages 7-9

  Filippatos, Theodosios D ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular risk; Ezetimibe; Low density lipoprotein; Statin

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; ANTILIPEMIC AGENT;

BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASES; HYPERCHOLESTEROLEMIA;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; EZETIMIBE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS;

EID: 84923196210     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104: 109-124.
2. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
3. Kearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
4. Boden WE, Probstfield JL, Anderson T, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267.
5. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
6. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
7. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
8. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-45.
9. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
10. Stitziel NO, Won HH, Morrison AC, et al; Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371: 2072-2082.
11. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-2026.
12. Cannon C. IMPROVE-IT Trial: A comparison of ezetimibe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association 2014 Scientific Sessions; November 17, 2014; Chicago, IL. Abstract.